ONCOGENES DIANA
ALK, anaplastic lymphoma kinase;
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer
1. Gerber DE et al.
Am Soc Clin Oncol Educ Book
2014:e353–65;
2. Pao W, Girard N.
Lancet Oncol
2011;12:175–80;
3. Perez-Moreno P et al.
Clin Cancer Res
2012;18:2443–51
Unknown oncogenic
drivers or oncogenic
drivers without
proven treatments
Unknown oncogenic
drivers or oncogenic
drivers without
proven treatments
EGFR M+
15–20%
! "#$%&"&''
()*'
+, - . &#$/#0. &%$
1'
EML4-ALK+
3–7%
EGFR M+ or
EML4-ALK+
<5%
! "#$%&' ( &#) #( *#+,"#
!"#$%&'
- . . /01213! 4- 451! 0#- "#678( 9:; +,8+&<=+#>?#( *#+,"#
!( #) '*"#$%+'
- . . /0@43- 45110#1"#A&B%*CD#
E8+F' +G( #%HI( &*J"#$&%HF( *7HK#L M3#N&%I*7,:; O( &I#PQC%BB#R7S 8+HO#- . ! 10#T"#6+C&%( #P>K#U7II#UV"#
,'*-.#'/ #$0-'
- . ! 101! 3! . @! 5/0#4"#$+H#W#( *#+,"#
*1%2&'
- . ! T0! T43T215/#
